References
- Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 2012; 397: 951-7. doi: 10.10007/s00423-012-0959-z
- Sarel AI, Yelluri S. Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg 2007; 142: 14349. doi: 10.1001/arch-surg.142.2.143
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Transtuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGa): a phase 3, open-label, randomised controlled trial. Lancet 2010; 37: 687-97. doi: 10.1016/s0140-6736(10)61121-x
- Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, et al, On behalf of EORTIC GITCG Group and JCOG SCGS Group. Current management of liver metastases from gastric cancer: what is common practise? New challenge of EORTIC and JCOG. Gastric Cancer 2017; 20: 904-12. doi: 10.1007/s10120-017-0696-7
- Kinoshita T, Kinoshita T, Saiua A, Esaki M, Sakamoto H, Yamanaka T. Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg 2015; 102: 102-7. doi: 10.1002/ bjs.9684
- Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzel E, Mühlbacher Jakesz R, et al. Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointestinal Surg 2002; 6: 682-9. doi: 10.1016/ s1091-255x(01)00075-0
- Schildberg CW, Croner R, Merkel S, Schellerer V, Müller V, Yedibela S, et al. Outcome of operative therapy of hepatic metastatic stomach carcinoma: A retrospective analysis. World J Surg 2012; 36: 872-8. doi: 10.1007/s00268-012-1492-5
- Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007; 95: 534-9. doi: 10.1002/jso.20739
- Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-96. doi: 10.1097/SLA.0b013e3181b13ca2
- Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Surg 2005; 12: 351-5. doi: 10.1007/s00534-005-0999-7
- Jiu-Yang Liu, Chun-Wei Peng, Xiao-Jun Yang, Chao-Qun Huang, Yan Li. The prognosis role of AJCC/UICC 8th Edition staging system in gastric cancer, a retrospective analysis. Am J Transl Res 2018; 10: 292-303. PMID: 29423014
- Tatsubayashi T, Tanizawa Y, Miki Y, Tokunaga M, Bando E, Kawamura T, et al. Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging. Gastric Cancer 2017; 20: 387-93. doi: 10.1007/s10120-016-0611-7
- Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-77. doi: 10.1200/JCO.2004.08.026
- Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. The surgical cooperative group. Lancet 1996; 347: 995-9. doi: 10.1016/ s0140-6736(96)90144-0
- Jung JO, Nienhüser H, Schleussner N, Schmidt T. Oligometastatic gastroesophageal adenocarcinoma: molecular pathophysiology and current therapeutic approach. Inter J Mol Sciences 2020; 21: 3-24. doi: 10.3390/ ijms21030951
- Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, et al. Kyushu Study Group of Clinical Cancer. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer 2016; 19: 968-76. doi: 10.1007/s10120-015-0530-z
- Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet 2016; 17: 309-18. doi: 10.1016/S1470-2045(15)00553-7
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55. 10.1093/ biomet/70.1.41
- Li M. Using the propensity score method to estimate causal effects: a review and practical guide. Organ Res Methods 2012; 15: 1-39. doi: 10.1177/1094428112447816 http://orm.sagepub.com
- Makino H, Kunisaki C, Izumisawa Y, Tokuhisa M, Oshima T, Nagano Y, et al. Indication for hepatiec resection in treatment of liver metastasis from gastric cancer. Anticancer Res 2010; 30: 2367-76. doi: 10.1016/S1470-2045(15)00553-7
- Fujitani K, Yang HK, Mizusawa J, Terashima M, Han SU, Iwasaki Y, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, ran-domised controlled trial. Lancet Oncol 2016; 17: 1-10. doi: 10.1016/S1470-2045(15)00553-7
- Ministrini S, Bencivenga M, Solaini L, Cipollari C, Sofia S, Marino E, et al. Stage IV gastric cancer: The surgical perspective of the Italian Research Group on Gastric Cancer. Cancers 2020; 12: 1-14. doi: 10.3390/cancers12010158